NCT06927180 2025-06-23SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCHenan Cancer HospitalPhase 2 Recruiting180 enrolled
NCT05659056 2024-04-16Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast CancerThe First Affiliated Hospital with Nanjing Medical UniversityPhase 2 Recruiting65 enrolled